Revillard J P, Vincent C, Clot J, Sany J
Eur J Rheumatol Inflamm. 1982;5(4):398-405.
Beta 2 microglobulin (beta 2m) is a 11,800 daltons polypeptide non covalently associated with the heavy chain of class I histocompatibility antigens (HLA-A, B and C) at the surface of nearly all cells. Serum beta 2m levels are passively controlled by the glomerular filtration rate. Increased beta 2m production resulting in elevated serum levels despite normal renal function have been reported in malignancies of the lymphoreticular system (e.g. multiple myeloma) and in various autoimmune or chronic inflammatory diseases, including rheumatoid arthritis. In some situations beta 2m levels were shown to be positively correlated with absolute lymphocyte counts in the peripheral blood or with the score of mononuclear cell infiltrates in biopsy specimens. Together with the demonstration that activated T lymphocytes release beta 2m in culture, these data support the hypothesis that increased production of beta 2m in vivo could represent a non specific indication of lymphocyte activation. Follow-up studies of individual patients are needed to define the clinical situations in which beta 2m determination may improve the immunological monitoring, with special reference to the early diagnosis of relapses and the assessment of individual response to treatment.
β2微球蛋白(β2m)是一种11,800道尔顿的多肽,与几乎所有细胞表面的I类组织相容性抗原(HLA - A、B和C)重链非共价结合。血清β2m水平受肾小球滤过率被动控制。尽管肾功能正常,但在淋巴网状系统恶性肿瘤(如多发性骨髓瘤)以及包括类风湿关节炎在内的各种自身免疫性或慢性炎症性疾病中,已报道β2m产生增加导致血清水平升高。在某些情况下,β2m水平与外周血绝对淋巴细胞计数或活检标本中单核细胞浸润评分呈正相关。连同活化T淋巴细胞在培养中释放β2m的证明,这些数据支持这样的假设,即体内β2m产生增加可能代表淋巴细胞活化的非特异性指标。需要对个体患者进行随访研究,以确定β2m测定可改善免疫监测的临床情况,特别是对于复发的早期诊断和个体对治疗反应的评估。